← Eichor
Study identifier: NCT06004674 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

Condition: Adverse Pregnancy Outcome  ·  Sponsor: Endeavor Health

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersNo

About this study

The goal of this randomized clinical trial is to evaluate if we can use placental pathology in a prior pregnancy which had an adverse outcome, such as early delivery, stillbirth, a baby born smaller than expected, or severe forms of high blood pressure during pregnancy, to guide treatment in the subsequent pregnancy and reduce risk of recurrent adverse pregnancy events. The main questions it aims to answer are: * Whether enoxaparin prevents recurrent adverse pregnancy outcomes among patients with a prior adverse pregnancy outcome that occurred in the setting of maternal vascular malperfusion (MVM). * If enoxaparin reduces the occurrence or severity of MVM among patients with a prior adverse pregnancy outcome that occurred in the setting of MVM.

This description comes directly from the study's public registry record.

Talk to the study team

Sunitha Suresh  ·  (847) 570-2860  ·  SSuresh@northshore.org

Kate Honeyfield  ·  847-570-2243  ·  KHoneyfield@northshore.org

Always discuss trial participation with your own doctor first.

Locations (1)

NorthShore University HealthSystemEvanston, Illinois, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06004674